^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    Serotonin reuptake inhibitor

    Related drugs:
    2d
    Cistanche tubulosa phenylethanol glycoside liposome ameliorates oxaliplatin-induced peripheral neuropathy by promoting RNA N6-methyladenosine modification. (PubMed, Phytomedicine)
    CPhG alleviates oxaliplatin-induced peripheral neuropathy by dual mechanisms: reducing neuroinflammation via IL-6 suppression and promoting neuronal survival and regeneration through AKT activation and m6A-dependent epitranscriptomic regulation. Compared with duloxetine, CPhG demonstrated superior neuroprotective and anti-inflammatory effects, supporting its potential as a novel therapeutic agent for OIPN.
    Journal
    |
    IL6 (Interleukin 6) • FTO (Alpha-Ketoglutarate-Dependent Dioxygenase FTO) • METTL14 (Methyltransferase 14) • METTL3 (Methyltransferase Like 3)
    |
    oxaliplatin
    4d
    Rapid Antidepressant Effects of Low-Dose Intravenous Esketamine in Patients with Chronic Pain (ChiCTR2500111749)
    P4, N=450, Not yet recruiting, Shandong Provincial Hospital Affiliated to Shandong First Medical University; Shandong Provincial Hospital Affiliated to Shandong First Medical Univer
    New P4 trial
    7d
    The Efficacy and Safety of Short Term S-ketamine Infusion as an Adjunctive Therapy in Patients With Fibromyalgia (clinicaltrials.gov)
    P=N/A, N=106, Recruiting, Beijing Tiantan Hospital | N=400 --> 106
    Enrollment change
    11d
    The Analgesic Efficacy and Safety of Venlafaxine in Patients With Herpes Zoster (clinicaltrials.gov)
    P=N/A, N=750, Recruiting, Beijing Tiantan Hospital
    New trial
    12d
    Desvenlafaxine for Preventive Treatment of Frequent Episodic Tension-type Headache (clinicaltrials.gov)
    P=N/A, N=432, Active, not recruiting, Tongji Hospital
    New trial
    12d
    Irritable Bowel Syndrome (IBS) Functional Magnetic Resonance Imaging (fMRI) With Desipramine (clinicaltrials.gov)
    P=N/A, N=18, Terminated, Washington University School of Medicine | N=70 --> 18 | Completed --> Terminated; Due to changes in trial personnel (co-investigator and research coordinator leaving the institution).
    Enrollment change • Trial termination
    13d
    Combination of Duloxetine and Pregabalin to Improve Postoperative Pain (clinicaltrials.gov)
    P1, N=90, Completed, Cairo University | Not yet recruiting --> Completed | Trial completion date: Jun 2023 --> Jan 2026 | Trial primary completion date: May 2023 --> Dec 2025
    Trial completion • Trial completion date • Trial primary completion date
    13d
    MACS-2: Efficacy of Two Doses of Duloxetine & Amitriptyline in Interstitial Lung Disease-related Cough (clinicaltrials.gov)
    P2, N=25, Recruiting, Mayo Clinic | Trial completion date: Dec 2025 --> Oct 2026 | Trial primary completion date: Dec 2025 --> Oct 2026
    Trial completion date • Trial primary completion date
    |
    amitriptyline
    13d
    MACS-1: Efficacy of Two Doses of Duloxetine and Amitriptyline in Subjects With Refractory Chronic Cough (clinicaltrials.gov)
    P2, N=50, Recruiting, Mayo Clinic | Trial completion date: Dec 2025 --> Dec 2026 | Trial primary completion date: Dec 2025 --> Dec 2026
    Trial completion date • Trial primary completion date
    |
    amitriptyline
    18d
    Different Transcutaneous Electrical Nerve Stimulation Modes in Pudendal Neuralgia Post-prostatectomy (clinicaltrials.gov)
    P=N/A, N=60, Completed, Cairo University
    New trial
    18d
    A Study of CSTI-500 in Patients With Prader-Willi Syndrome (clinicaltrials.gov)
    P2, N=12, Not yet recruiting, ConSynance Therapeutics
    New P2 trial
    26d
    I-COAP: Prescription Opioids, Brain Structure, and Cognition in Older Adults With Chronic Pain (clinicaltrials.gov)
    P2, N=200, Recruiting, Mayo Clinic | Trial completion date: Dec 2031 --> Dec 2029 | Trial primary completion date: Dec 2030 --> Jul 2029
    Trial completion date • Trial primary completion date